Erasca Unveils First Clinical Candidates, Aims To Create A MAPK Clamp
SHP2, ERK Inhibitors Disclosed After Two Years, $300m In Funding
Former Ignyta CEO’s well-funded Erasca obtained its first clinical-stage precision oncology candidates from NiKang and Asana, eyeing a first-in-class approach to RAS/MAPK-driven cancers.
You may also be interested in...
Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings.
Private Company Edition: venBio’s new fund plus Ysios Capital’s recent €216m ($260m) fund adds up to $810m in fresh venture capital for life science companies. Also, Nikang and Esco attracted $200m each in VC investment, Pulmocide closed a $92m series C round and Stablix launched with $63m.
Private Company Edition: In addition to Erasca’s big series B round, Mabwell reportedly brought in $278m. Also, Kurma, Venrock and Section bring the number of new VC funds in April to eight, raising $5.89bn, and former AveXis execs launched the new gene therapy venture Taysha.